-
Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.
DiabetesGreenbaum CJ, Speake C, Krischer J, Buckner JH, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA -
Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.
DiabetesMarré ML, McGinty JW, Chow IT, DeNicola ME, Beck NW, Kent SC, Powers AC, Bottino R, Harlan DM, Greenbaum CJ, Kwok WW, Piganelli JD, James EA -
Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.
Diabetes CareBingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ -
Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.
J Clin Endocrinol MetabHao W, Woodwyk A, Beam C, Bahnson HT, Palmer JP, Greenbaum CJ -
Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
JAMAWriting Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group., Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ -
Understanding and preventing type 1 diabetes through the unique working model of TrialNet.
DiabetologiaBattaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark A, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M -
Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease.
J ImmunolBuckner JH, Greenbaum CJ -
Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes.
Curr Diab RepGreenbaum CJ, Lord S, VanBuecken DE -
Measurement of Pro-Islet Amyloid Polypeptide (1-48) in Diabetes and Islet Transplants.
J Clin Endocrinol MetabCourtade JA, Klimek-Abercrombie AM, Chen YC, Patel N, Lu PYT, Speake C, Orban PC, Najafian B, Meneilly G, Greenbaum CJ, Warnock GL, Panagiotopoulos C, Verchere CB -
Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes.
J ImmunolCerosaletti K, Barahmand-Pour-Whitman F, Yang J, DeBerg HA, Dufort MJ, Murray SA, Israelsson E, Speake C, Gersuk VH, Eddy JA, Reijonen H, Greenbaum CJ, Kwok WW, Wambre E, Prlic M, Gottardo R, Nepom GT, Linsley PS -
Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to β Cell Antigens Are Focused on a Unique Set of Epitopes.
J ImmunolYang J, Wen X, Xu H, Torres-Chinn N, Speake C, Greenbaum CJ, Nepom GT, Kwok WW -
Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home.
Clin Exp ImmunolSpeake C, Whalen E, Gersuk VH, Chaussabel D, Odegard JM, Greenbaum CJ -
Dissecting heterogeneity in paediatric Type 1 diabetes: association of TCF7L2 rs7903146 TT and low-risk human leukocyte antigen (HLA) genotypes.
Diabet MedRedondo MJ, Grant SF, Davis A, Greenbaum CJ, T1D Exchange Biobank. -
Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.
Diabetes CareHao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. -
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.
Sci Transl MedHundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH
